A Multicenter, Open-Label Study to Assess the Efficacy and Safety of Infliximab (REMICADE) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL).
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2012
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PSUNRISE
- Sponsors Centocor; Janssen Biotech
- 31 Aug 2018 Biomarkers information updated
- 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2009 Actual number of patients (217) added as reported by ClinicalTrials.gov.